WEE1 and head and neck squamous cell carcinoma: To assess whether the dual inhibition of PARP and Wee1 may exert some additive or synergistic effects in HPV-positive HNSCC cells, we tested a combination of the PARP inhibitor olaparib and the Wee1 inhibitor adavosertib (MK-1775/AZD-1775) with regard to cell proliferation and cell cycle distribution.